Moreover, significantly increased phosphorylation of Smad3 and decreased phosphorylation of Smad1/5/9 were detected in MMC-treated rats and PAH patients, suggesting the imbalance of Smad pathways during the PAH process. Here, SMAD3 is linked to pulmonary arterial hypertension.